These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34718518)

  • 21. Sodium-glucose co-transporter-2 inhibitors and protection from cardiovascular death: Is it all about heart failure?
    Caruso I; Cignarelli A; Laviola L; Giorgino F
    Diabetes Obes Metab; 2021 Sep; 23(9):2194-2196. PubMed ID: 34033214
    [No Abstract]   [Full Text] [Related]  

  • 22. The role of sodium glucose co-transporter inhibitors in heart failure prevention.
    Garla V; Subauste A; Butler J; Lien LF
    J Diabetes Complications; 2021 Mar; 35(3):107811. PubMed ID: 33280983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Serendipity of sodium-glucose co-transporter 2 inhibitors: a new paradigm in the management of heart failure with reduced ejection fraction].
    Rosano G; Iacoviello M; Filardi PP
    G Ital Cardiol (Rome); 2021 Apr; 22(4):277-283. PubMed ID: 33783447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry.
    Becher PM; Schrage B; Ferrannini G; Benson L; Butler J; Carrero JJ; Cosentino F; Dahlström U; Mellbin L; Rosano GMC; Sinagra G; Stolfo D; Lund LH; Savarese G
    Eur J Heart Fail; 2021 Jun; 23(6):1012-1022. PubMed ID: 33599357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-Analysis Evaluating the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction According to Baseline Anemia.
    Patoulias D; Papadopoulos C; Fragakis N; Karagiannis A; Doumas M
    Am J Cardiol; 2022 Sep; 179():111-114. PubMed ID: 35871863
    [No Abstract]   [Full Text] [Related]  

  • 26. Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus.
    Fralick M; Colacci M; Thiruchelvam D; Gomes T; Redelmeier DA
    Diabetes Obes Metab; 2021 Apr; 23(4):950-960. PubMed ID: 33336894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of sodium-glucose co-transporter-2 inhibitors in patients with kidney transplantation and diabetes mellitus.
    Yeggalam A; Liebich JA; Yu K; Shrestha E; Nadella S; Ahir V; Newman J; Lentine KL; Caliskan Y; Abu Al Rub F; Dhindsa S; Albert SG
    Diabetes Obes Metab; 2023 Jun; 25(6):1777-1780. PubMed ID: 36846956
    [No Abstract]   [Full Text] [Related]  

  • 28. Cardio-Protective Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: Focus on Heart Failure.
    Karangelis D; Mazer CD; Stakos D; Tzifa A; Loggos S; Verma S; Mitropoulos F
    Curr Pharm Des; 2021; 27(8):1051-1060. PubMed ID: 33143620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of heart failure with sodium glucose co-transporter-2 inhibitors in people with type 2 diabetes mellitus: current evidence and future directions.
    Sharma A; Butler J; Zieroth S; Giannetti N; Verma S
    Diabet Med; 2019 Dec; 36(12):1550-1561. PubMed ID: 31536660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comment on: Acute abdomen as a side-effect of sodium-glucose co-transporter 2 inhibitors in diabetic patients.
    Patoulias D; Patoulias I
    Br J Surg; 2022 Mar; 109(4):e67. PubMed ID: 35020821
    [No Abstract]   [Full Text] [Related]  

  • 31. A hypothesis for why sodium glucose co-transporter 2 inhibitors have been found to cause genital infection, but not urinary tract infection.
    Fralick M; MacFadden DR
    Diabetes Obes Metab; 2020 May; 22(5):755-758. PubMed ID: 31943733
    [No Abstract]   [Full Text] [Related]  

  • 32. Sodium-glucose co-transporter 2 inhibitors and acute heart failure.
    Groenewegen A; Rutten FH
    Eur J Heart Fail; 2020 Apr; 22(4):723-725. PubMed ID: 32072715
    [No Abstract]   [Full Text] [Related]  

  • 33. Author response to: Acute abdomen as a side-effect of sodium-glucose co-transporter 2 inhibitors in diabetic patients.
    Kietaibl AT; Fasching P; Glaser K; Petter-Puchner AH
    Br J Surg; 2022 Mar; 109(4):e68. PubMed ID: 35020810
    [No Abstract]   [Full Text] [Related]  

  • 34. Sodium-glucose co-transporter 2 inhibitors in heart failure.
    Rosano GMC; Vitale C; Savarese G
    Eur Heart J Cardiovasc Pharmacother; 2021 May; 7(3):e9-e10. PubMed ID: 33576409
    [No Abstract]   [Full Text] [Related]  

  • 35. CHIEF Effects of Sodium Glucose Co-Transporter Inhibitors on Health-Related Quality of Life in Heart Failure.
    Allen LA
    JACC Heart Fail; 2024 Apr; 12(4):719-721. PubMed ID: 38569825
    [No Abstract]   [Full Text] [Related]  

  • 36. Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure.
    Butler J; Handelsman Y; Bakris G; Verma S
    Eur J Heart Fail; 2020 Apr; 22(4):604-617. PubMed ID: 31926059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sodium-glucose co-transporter 2 inhibitors for heart failure: clinical trial efficacy and clinical practice effectiveness.
    Khan MS; Fonarow GC; Greene SJ
    Eur J Heart Fail; 2021 Jun; 23(6):1023-1025. PubMed ID: 33779013
    [No Abstract]   [Full Text] [Related]  

  • 38. Sodium-glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction.
    Monzo L; Ferrari I; Cicogna F; Tota C; Calò L
    Int J Cardiol; 2021 Oct; 341():56-59. PubMed ID: 34454968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism.
    Anker SD; Khan MS; Shahid I; Filippatos G; Coats AJS; Butler J
    Eur J Heart Fail; 2021 Aug; 23(8):1250-1255. PubMed ID: 34173305
    [No Abstract]   [Full Text] [Related]  

  • 40. Sodium-glucose co-transporter-2 inhibitor use and erythrocytosis: assessment of risk and need for referral to haematology.
    Gangat N; Tefferi A
    Nephrol Dial Transplant; 2023 Nov; 38(12):2670-2672. PubMed ID: 37468452
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.